



Review Article

Sexual function and its relationship with cannabis, tobacco, benzodiazepine and amphetamine-type stimulants use

Ajay Kumar¹, Sangha Mitra Godi², Arti Yadav³

¹Assistant Professor, Department of Psychiatry, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India

²Senior Resident, Department of Psychiatry, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India

³Senior Resident, Department of Psychiatry, Institute of Mental Health and Hospital, Agra, Uttar Pradesh, India

Date of Submission :

15 May 2021

Date of Acceptance :

19 May 2021

Keywords: Sexual function, Cannabis, Cocaine, Club-drugs, Amphetamine-type stimulants

Abstract

Substance use interacts with biopsychosocial factors in an intricate manner affecting the sexual function of an individual. Therefore, we attempted to discuss the impact of substance use on sexual function, focusing on cannabis, tobacco, Benzodiazepines (BZDs), cocaine, amphetamine, and amphetamine-type stimulant (ATs), and club drug.

Introduction

Our understanding has evolved about sexual health. In 1975, World Health Organisation (WHO) narrated sexual health as “the integration of the somatic, intellectual, emotional and social aspects of sexual being in ways that are positively enriching and that enhance personality, communication and love”(WHO, 1975). Subsequently, in 2006, WHO proposed a more inclusive definition, i.e., “Sexual health is a state of physical, emotional, mental and social well-being related to sexuality; it is not merely the absence of disease, dysfunction or infirmity” (WHO, 2006). The significance of sexual health is considered to be imperative to

general health and has been recognized as an “important public health concern” as early as two decades ago (Laumann et al., 1999).

Sexual function is a tenant of sexual health, linked to the performance of a sexual act by an individual. A normal sexual function results from normal sexual desire, arousal, orgasm, and ejaculation and is greatly influenced by several physicals, psychological, interpersonal, cultural, social, and gender factors (Briken et al., 2020; Hatzimouratidis and Hatzichristou, 2007; Lewis et al., 2004). Thus, any deviation in any of these domains can result in sexual dysfunction. In addition, sexual dysfunction leads to significant psychosocial stress, which adversely affects the quality of life of an individual (Wagner et al., 2000).

Substance use disorder (SUD), licit or illicit, is suggested to interact with various biopsychosocial factors in a complex way and affect the sexual function of an individual. SUD may worsen pre-existing sexual dysfunction, precipitated or maintained it

Corresponding author: Ajay Kumar

Email: ajaypgimer2016@gmail.com

How to cite article: Kumar, A., Godi, S., Yadav, A.

(2021). Sexual function and its relationship with cannabis, tobacco, benzodiazepine and amphetamine-type stimulants use. *Indian Journal of Health, Sexuality & Culture*, 7(1), 26-34.

DOI: 10.5281/zenodo.5151810

This article is distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

(Del Río et al., 2015; Ghadigaonkar and Murthy, 2019; Johnson et al., 2004). The secondary sexual dysfunction due to chronic substance use often appears from previously normal sexual functioning. Substances most involved are alcohol, tobacco, cannabis, opioids, followed by amphetamines, cocaine, inhalants, sedatives, etc. However, this review focussed on sexual function concerning substance use other than alcohol and opioids, i.e., cannabis, tobacco, BZDs, ATS and club drugs, etc.

Cannabis use and sexual function

Just like many other countries, in India, the entheogenic use of cannabis has been well accepted. In Atharva Veda, Cannabis sativa is outline das one of the five sacred plants that reduce anxiety and fear (Abel, 1982). It is the most consumed illicit substance, with 2.5% of the global population (approximately 147 million) using cannabis (Cohen et al., 2019). Around 13.1 million people reported as cannabis dependent in 2010 (Degenhardt et al., 2017).

In India, according to the recent national survey on the magnitude of substance use, 2.8% of the population of 10-75 years of age (3.1 crore individuals) uses cannabis in any form (Ambekar A et al, 2019). Following Alcohol, Cannabis is the next commonly used substance in India, used illegally as charas, hashish, etc., and legally available as bhang in some states.

Cannabis has a reputation as an aphrodisiac historically, the numbers of research also verifying its positive effect on sexual functions. Marijuana smoking shown to have increased sexual desire, increase sexual frequency, sexual satisfaction, and improves orgasm (Dawley et al., 1979; Koff, 1974; Sun and Eisenberg, 2017). The aphrodisiac effect of cannabis possibly explained by its property of loosening inhibition, enhance

sensate focus, increased sense of enjoyment (hedonism), slow perception of time, which perceived as prolonged pleasure, and its reputation as a sexual enhancer (placebo effect) (Ashton, 2001; Halikas et al., 1982; Jarvik ME, 1976). At the same time, long-term use of cannabis is linked to a range of sexual problems too. A study from Australia shown a significant association between the frequency of cannabis use and the numbers of sexual partners in both genders (Smith et al., 2010). A recent meta-analysis also reported that cannabis users had a two-fold higher risk of developing erectile dysfunction compared to controls (Pizzol et al., 2019). The chronic use of cannabis also affects semen quality; a 30% reduction is shown in sperm concentration if cannabis is used more than once per week (Gundersen et al., 2015).

The growing evidence suggests that tetrahydrocannabinol (THC) interacts with the overall endocannabinoid system (ECS) throughout the body. The central nervous system mainly has CB1 receptors, while the peripheral system primarily has CB2 receptors and some CB1 receptors. Centrally, CB1 receptors are concentrated in the hippocampus, hypothalamus, cerebral cortex, amygdala, and cerebellum. These receptors are also present in vital organs for sexual hormones and fertility in humans, i.e., the adrenal gland and ovaries (Lynn et al., 2020).

Tobacco use and sexual function

WHO reported that the global trend of tobacco use reflects one-third of the world population of 15 years and above were users of some form of tobacco (WHO, 2019). In addition, 28.6% (266.8 million) of 15 years and above age group uses tobacco globally (Global Adult Tobacco Survey, GATS 2, 2018). Tobacco use, smoke or smokeless, known to have a range of deleterious effects

on sexual health cause harm to sexual health (Harte and Meston, 2008; Olsen J, Rachootin P, Schiødt AV, 1983; Sansone et al., 2018; Sharma et al., 2016). More than 4700 chemicals have been identified in cigarette smoke, including cadmium, arsenic, and lead implicated in male fertility (Borgerding and Klus, 2005; Jurasovi et al., 2004). Chronic smoking and compromised lungs result in hypoxia, impairing spermatogenesis (Gabrielsen and Tanrikut, 2016). Furthermore, several micro-toxins affect the mitochondrial function and chromatin structure of human sperm, reducing its fertilization capacity (Sharma et al., 2016). Smoking reduces sperm count and motility, causing infertility (Sansone et al., 2018; Sharma et al., 2016). Smoking is one of the independent risk factors for erectile dysfunction due to its strong vasoconstrictor effect (Chew et al., 2009; Harte, 2014). Cigarette smoke and its components reduce neuronal nitric-oxide synthase activity in penile tissue. Nicotine also reduces other vasoactive substances such as endothelium-derived relaxing factors, perhaps results in erectile dysfunction (Demady et al., 2003).

Smoking prevalent among women too, about 30% of women of reproductive age smoke (Penzias et al., 2018). Studies on the effects of smoking on female sexual function (FSD) are very few. An epidemiological study recognized the implication of smoking on FSD as early as 1983 (Olsen, 1983). The subsequent report suggests that just like male sexual dysfunction, smoking is an independent risk factor for FSD (Choi et al., 2015). Moreover, the severity of FSD is correlated with the amount of smoking, i.e., pack-year (Choi et al., 2015). Contrary to this, another study found that smoking status associated with increased sexual desire, while nicotine dependence correlated with lower sexual desire and increased sexual problems (Costa and Peres, 2015).

Benzodiazepine uses and sexual function

BZDs are the most prescribed psychotropic agents by physicians and psychiatrists in clinical practice as an add-on medication. The effect of benzodiazepine on sexual function are scarcely documented. Only limited studies, including retrospective / prospective and a few case reports, found benzodiazepines were linked to sexual dysfunction (Hosseinzadeh Zoroufchi et al., 2021). Clonazepam has the maximum propensity to cause sexual dysfunction compared to alprazolam, diazepam, and lorazepam in male veterans with post-traumatic stress disorder (PTSD). The prevalence of sexual dysfunction, primarily ED, has shown to have a prevalence as high as 42.9% with clonazepam (Fossey and Hamner, 1994). The alprazolam was also found to have dose-dependent sexual problems, i.e., decreased libido, erectile dysfunction (Kaufman et al., 2018; Lydiard RB et al., 1987). There are anecdotal reports of sexual disinhibition and increased promiscuous behavior with clonazepam and diazepam withdrawal (Fava and Borofsky, 1991; Nutt et al., 1986).

Cocaine use and sexual function

Cocaine, a psychostimulant and a potent dopamine agonist, can be used as snort, smoke, or injection (Nestler, 2005). The global prevalence of cocaine dependence is estimated to be around 52.5 per 100 000 (Peacock et al., 2018). In India, a small proportion of the population (male-0.18%, female-0.01%) currently use cocaine (Ambekar A et al., 2019).

The short-term use of cocaine can enhance sexual function, but chronic cocaine use may result in sexual dysfunction, including decreased sexual desire and erectile dysfunction (Warner, 1993; Weatherby et al.,

1992). The prevalence of ED was found as high as 66% in regular cocaine users for 1 year or longer (Cocores et al., 1988). Moreover, increased sex trading and drug paddling are fairly associated with crack use (Weatherby et al., 1992). The intracavernosal injection of cocaine is known to cause priapism (Jansen and Theron, 2006).

The effect of cocaine on FSD is far less explored; contrary to the widespread assumption that cocaine acts as an aphrodisiac, cocaine use was found to reduced sexual desire and increased sexual dysfunction (Henderson et al., 1995).

Use of amphetamine-type stimulant (ATS), 'designer drugs' and sexual function

Right after discovering amphetamine in 1920, a series of amphetamine-based stimulants was synthesized, and soon their abuse potential was recognized. These amphetamine-based stimulants later popularised as amphetamine-type stimulants (ATS) (Rasmussen, 2015). The use of ATS is perhaps highlighted due to its association with risky sexual behavior and sexually transmitted diseases (STDs) (Jia et al., 2013). In India, a modest proportion of 0.18% (i.e., about 19.4 lakh individuals) is estimated to use ATS in harmful or dependent patterns (Ambekar A et al., 2019). Range of sexual problems such as decreased sexual desire, increase latency, and ED found associated with amphetamine use (Bang-Ping, 2009; Chou et al., 2015). Amphetamines most likely interfere with the central nervous system and act as neurotoxins, probably impair penile smooth muscle and endothelial function (Chou et al., 2015).

Another ATS, 3,4-Methylene dioxymethamphetamine (MDMA or Ecstasy), has hallucinogenic property. One-year prevalence of hallucinogen use in India is about 0.12% of

the population, i.e., approximately 12.6 lakh individuals (Ambekar et al., 2019). MDMA is associated with high-risk sexual behavior due to sexual disinhibition and enhanced sexual experience (Bang-Ping, 2009). In one of the studies, the use of MDMA associated with increases sexual desire delayed but an intense orgasm and 40% of ED among male subjects (Zemishlany et al., 2001). Amphetamines, due to their sympathomimetic property, result in vasoconstriction, therefore, causes vascular erectile dysfunction (Abekawa et al., 2001).

Methamphetamine, one of the amphetamine derivatives, popularly known as 'crystal meth', 'ice', 'crank', and 'speed'. Like other designer amphetamines, this drug also produces feelings of energy, euphoria, and a 'high' (Comer et al., 2001). However, it induced central dopamine depletion and cause neurotoxicity (Abekawa et al., 2001).

Methamphetamine, gamma-hydroxybutyrate (GHB), MDMA, ketamine ('Special K'), lysergic acid diethylamide (LSD) and Rohypnol (flunitrazepam) collective popularised as 'club drug' or 'party drug' (NIDA, 2004). Use of these drugs popular among youth in special circuit parties with loud techno-rock music, laser light, and 'night clubs' termed as 'rave party' (Rome, 2001). The growing popularity of rave culture or 'rave party' in India also a matter of concern (Chakraborty et al., 2011). These drugs can decrease sexual inhibition and intern enhances vulnerability for risky sexual practices. A strong link has been found between the sexual choices of bisexual men and gay with the use of club drugs at circuit parties (Colfax et al., 2001).

The 'club drug' especially important due to its connexion with 'chem sex' representing sexual practice where 'club drug' used during sex to enhance the sexual experience; it

mainly popular among communities of men who have sex with men (MSM) (Bourne A et al., 2014). The use of 'club drug' prevalent among gay and bisexual men (Isaiah Green and Halkitis, 2006).

Gamma-hydroxybutyrate (GHB) impart increase feelings of relaxation, euphoria, and sexual disinhibition (Miotto, Jack Darakjian, Janice Basc, 2001). Although, it is known as a 'date rape' drug as it can be mixed with alcohol in liquid form without altering its taste, the increased sexual feeling and amnesia under its intoxication incapacitate the victim of sexual abuse of a perpetrator (Schwartz et al., 2000).

Ketamine, the anaesthetic agent, was abused owing to cause technicolor, vivid visual and auditory hallucinations (Wong and Jenkins, 1974). Chronic use of ketamine is most likely associated with ED (Shang et al., 2017).

It can be concluded that SUD is entwined with several bio psycho social and cultural factors and poses serious implications to sexual functions manifested as a range of sexual dysfunctions. Many of these substances are perceived to have sexual enhancing properties, but most research supports their deleterious impact on sexual function on long-term use.

Summary box: impact of SUD on sexual function

1. Cannabis
 - ◆ Most widely cultivated and consumed substance worldwide
 - ◆ A strong image of an aphrodisiac and wider entheogenic acceptability
 - ◆ Chronic use associated with orgasmic dysfunction in men, ED and poor semen quality.
2. Tobacco
 - ◆ Smoking; an independent factor for ED
 - ◆ Smoking; an independent risk factor for FSD
3. BZDs
 - ◆ Range of sexual problems like ED and decreased libido associated with chronic use of clonazepam and alprazolam.
 - ◆ Scattered reports of sexual disinhibition and increase libido also present.
4. Cocaine
 - ◆ Chronic use of cocaine causes sexual dysfunction, including decreased sexual desire and erectile dysfunction.
5. ATS
 - ◆ The use of ATS is associated with risk-taking sexual behavior and sexually transmitted diseases (STDs).
 - ◆ MDMA causes delayed orgasm and ED.
6. GHB
 - ◆ Has a reputation of 'Date rape' drug.
7. Ketamine
 - ◆ Long-term use of ketamine found to cause ED.

Acknowledgements: None

Declaration of interests: None

References

Abekawa T, Ohmori T, Honda M, et al. (2001). Effect of low doses of L-NAME on methamphetamine-induced dopaminergic depletion in the rat striatum. *Journal of neural transmission*, 108(11): 1219-30.

Abel EL (1982). *Marihuana, the First Twelve Thousand Years*. United States: McGraw-Hill.

Adam Bourne, David Reid, Ford Hickson, Sergio Torres Rueda PW. (2014). *The Chemsex study: drug use in sexual settings among gay and bisexual men in Lambeth, Southwark, and Lewisham*. Stigma Research, London School of Hygiene & Tropical medicine, London. London. Available at: <https://researchonline.lshtm.ac.uk/id/eprint/2197245> (accessed 18 May 2021).

Ashton CH. (2001). Pharmacology and effects of cannabis: A brief review. *British Journal of Psychiatry*, 178(2), 101-106.

Atul Ambekar, Rakesh Kumar Chadda, Sudhir Kumar Khandelwal, Ravindra Rao, Ashwani Kumar, Mishra AA. (2019). *Magnitude of Substance Use in India*. Ministry of Social Justice and Empowerment, Government of India. New Delhi.

Bang-Ping J. (2009). Sexual Dysfunction in Men Who Abuse Illicit Drugs: A Preliminary Report. *The Journal of Sexual Medicine*, 6(4), 1072-1080.

Borgerding M., Klus H. (2005). Analysis of complex mixtures - Cigarette smoke. *Experimental and Toxicologic Pathology*, 57, 43-73.

Briken P, Matthiesen S, Pietras L, et al. (2020). Estimating the Prevalence of Sexual Dysfunction Using the New ICD-11 Guidelines. *Deutsches Aertzblatt Online*.

Chakraborty K, Neogi R, Basu D. (2011). Club drugs: review of the 'rave' with a note of concern for the Indian scenario. *The Indian journal of medical research*, 133, 594-604.

Chew K-K, Bremner A, Stuckey B, et al. (2009).

Is the Relationship Between Cigarette Smoking and Male Erectile Dysfunction Independent of Cardiovascular Disease? Findings from a Population-Based Cross-Sectional Study. *The Journal of Sexual Medicine*, 6(1), 222-231.

Choi J, Shin DW, Lee S, et al. (2015). Dose-response relationship between cigarette smoking and female sexual dysfunction. *Obstetrics & Gynecology Science*, 58(4), 302.

Chou N, Huang Y, Jiann B. (2015). The Impact of Illicit Use of Amphetamine on Male Sexual Functions. *The Journal of Sexual Medicine*, 12(8), 1694-1702.

Cocores JA, Miller NS, Pottash AC, et al. (1988). Sexual Dysfunction in Abusers of Cocaine and Alcohol. *The American Journal of Drug and Alcohol Abuse*, 14(2), 169-173.

Cohen K, Weizman A and Weinstein A. (2019). Positive and Negative Effects of Cannabis and Cannabinoids on Health. *Clinical Pharmacology & Therapeutics*, 105(5), 1139-1147.

Colfax GN, Mansergh G, Guzman R, et al. (2001). Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. *Journal of acquired immune deficiency syndromes*, 28(4), 373-9.

Comer S, Hart C, Ward A, et al. (2001). Effects of repeated oral methamphetamine administration in humans. *Psychopharmacology*, 155(4), 397-404.

Costa RM, Peres L. (2015). Smoking is Unrelated to Female Sexual Function. *Substance Use & Misuse*, 50(2), 189-194.

Dawley HH, Baxter AS, Winstead DK, et al. (1979). An attitude survey of the effects of marijuana on sexual enjoyment. *Journal of Clinical Psychology*, 35(1), 212-217.

Degenhardt L, Ferrari AJ and Hall WD. (2017). The Global Epidemiology and Disease Burden of Cannabis Use and Dependence. In: *Handbook of Cannabis and Related Pathologies*. Elsevier, pp. 89-100.

Del Río FJ, Cabello F, Fernández I. (2015). Influence of substance use on the erectile response in a sample of drug users. *International Journal*

- of Clinical and Health Psychology, 15(1), 37-43.
- Demady DR, Lowe ER, Everett AC, et al. (2003). Metabolism-based Inactivation of neuronal nitric-oxide synthase by components of cigarette and cigarette smoke. *Drug Metabolism and Disposition*, 31(7),932-937.
- Fava M, Borofsky GF. (1991). Sexual Disinhibition during Treatment with a Benzodiazepine: A Case Report. *The International Journal of Psychiatry in Medicine*, 21(1), 99-104.
- Fossey MD, Hamner MB. (1994). Clonazepam-related sexual dysfunction in male veterans with PTSD. *Anxiety*, 1(5),233-6.
- Gabrielsen JS, Tanrikut C. (2016). Chronic exposures and male fertility: the impacts of environment, diet, and drug use on spermatogenesis. *Andrology*, 4(4),648-661.
- Ghadigaonkar DS, Murthy P. (2019). Sexual Dysfunction in Persons With Substance Use Disorders. *Journal of Psychosexual Health*, 1(2), 117-121.
- Global Adult Tobacco Survey, GATS 2. (2018). Available at: <https://ntcp.nhp.gov.in/assets/document/surveys-reports-publications/Global-Adult-Tobacco-Survey-Second-Round-India-2016-2017.pdf>.
- Gundersen TD, Jørgensen N, Andersson A-M, et al. (2015). Association Between Use of Marijuana and Male Reproductive Hormones and Semen Quality: A Study Among 1,215 Healthy Young Men. *American Journal of Epidemiology*, 182(6), 473-481.
- Halikas J, Weller R and Morse C. (1982). Effects of Regular Marijuana Use on Sexual Performance. *Journal of Psychoactive Drugs*, 14(1-2), 59-70.
- Harte CB. (2014). Implication of Cigarette Smoking and Cessation on Sexual Function in Men and Women. *Current Sexual Health Reports*, 6(4), 220-234.
- Harte CB and Meston CM. (2008). Acute Effects of Nicotine on Physiological and Subjective Sexual Arousal in Nonsmoking Men: A Randomized, Double-Blind, Placebo-Controlled Trial. *The Journal of Sexual Medicine*, 5(1),110-121.
- Hatzimouratidis K, Hatzichristou D. (2007). Sexual Dysfunctions: Classifications and Definitions. *The Journal of Sexual Medicine*, 4(1),241-250.
- Henderson DJ, Boyd CJ and Whitmarsh J (1995) Women and illicit drugs: Sexuality and crack cocaine. *Health Care for Women International*, 16(2),113-124.
- Hosseinzadeh Zoroufchi B, Doustmohammadi H, Mokhtari T, et al. (2021). Benzodiazepines related sexual dysfunctions: A critical review on pharmacology and mechanism of action. *Revista Internacional de Andrología*, 19(1),62-68.
- Isaiah Green A, Halkitis PN (2006). Crystal methamphetamine and sexual sociality in an urban gay subculture: An elective affinity. *Culture, Health & Sexuality*, 8(4),317-333.
- Jansen KLR, Theron L (2006). Ecstasy (MDMA), Methamphetamine, and Date Rape (Drug-Facilitated Sexual Assault): A Consideration of the Issues. *Journal of Psychoactive Drugs*, 38(1),1-12.
- Jarvik ME BE. (1976). Sexual effects of drugs. In: *Textbook of Sexology*. Amsterdam: Elsevier, Excerpta Medica.
- Jia Z, Yan S, Bao Y, et al. (2013). Sexual Behavior Differences Between Amphetamine-Type Stimulants Users and Heroin Users. *Journal of Addiction Medicine*, 7(6),422-427.
- Johnson SD, Phelps DL, Cottler LB. (2004). The Association of Sexual Dysfunction and Substance Use Among a Community Epidemiological Sample. *Archives of Sexual Behavior*, 33(1),55-63.
- Jurasovi J, Cvitkovi P, Pizent A, et al. (2004). Semen quality and reproductive endocrine function with regard to blood cadmium in Croatian male subjects. *BioMetals*, 17(6),735-743.
- Kaufman KR, Coluccio M, Linke M, et al. (2018). Alprazolam-induced dose-dependent anorgasmia: case analysis. *BJPsych Open*, 4(4),274-277.
- Koff WC. (1974). Marijuana and sexual activity. *The Journal of Sex Research*, 10(3), 194-204.

- Laumann EO, Paik A, Rosen RC. (1999) Sexual Dysfunction in the United States. *JAMA*, 281(6), 537.
- Lewis RW, Fugl Meyer KS, Bosch R, et al. (2004). Epidemiology/Risk Factors of Sexual Dysfunction. *The Journal of Sexual Medicine*, 1(1), 35-39.
- Lydiard RB, Howell EF, Laraia MT, et al. (1987). Sexual side effects of alprazolam. *The American journal of psychiatry*, 144(2), 254-5.
- Lynn B, Gee A, Zhang L, et al. (2020). Effects of Cannabinoids on Female Sexual Function. *Sexual Medicine Reviews*, 8(1), 18-27.
- Miotto, Jack Darakjian, Janice Basc K. (2001). Gamma-Hydroxybutyric Acid: Patterns of Use, Effects and Withdrawal. *American Journal on Addictions*, 10(3), 232-241.
- Nestler EJ. (2005). The neurobiology of cocaine addiction. *Science & practice perspectives*, 3(1), 4-10.
- NIDA. (2004). Community Drug Alert Bulletin - Club Drugs. Available at: [https:// archives.drugabuse.gov/publications/nida-community-drug-alert-bulletin-club-drugs](https://archives.drugabuse.gov/publications/nida-community-drug-alert-bulletin-club-drugs) (accessed 18 May 2021).
- Nutt D, Hackman A, Hawton K (1986). increased sexual function in benzodiazepine withdrawal. *The Lancet*, 328(8515), 1101-1102.
- Olsen J, Rachootin P, Schiødt AV DN. (1983). Tobacco Use, Alcohol Consumption and Infertility. *International Journal of Epidemiology*, 12(2), 179-184.
- Peacock A, Leung J, Larney S, et al. (2018). Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. *Addiction*, 113(10), 1905-1926.
- Penzias A, Bendikson K, Butts S, et al. (2018). Smoking and infertility: a committee opinion. *Fertility and Sterility*, 110(4), 611-618.
- Pizzol D, Demurtas J, Stubbs B, et al. (2019). Relationship Between Cannabis Use and Erectile Dysfunction: A Systematic Review and Meta-Analysis. *American journal of men's health*, 13(6), 1557988319892464.
- Rasmussen N. (2015). Amphetamine-Type Stimulants., pp. 9-25. DOI: 10.1016/bs.irn.2015.02.001.
- Rome ES. (2001). It's a brave new world: rave culture and illicit drug use in the young. *Cleveland Clinic Journal of Medicine*, 68(6), 541-550.
- Sansone A, Di Dato C, de Angelis C, et al. (2018). Smoke, alcohol and drug addiction and male fertility. *Reproductive Biology and Endocrinology*, 16(1). 3.
- Schwartz RH, Milteer R, LeBeau MA. (2000). Drug-facilitated sexual assault ('date rape'). *Southern medical journal*, 93(6), 558-61.
- Shang H-S, Wu Y-N, Liao C-H, et al. (2017). Long-term administration of ketamine induces erectile dysfunction by decreasing neuronal nitric oxide synthase on cavernous nerve and increasing corporal smooth muscle cell apoptosis in rats. *Oncotarget*, 8(43), 73670-73683.
- Sharma R, Harlev A, Agarwal A, et al. (2016). Cigarette Smoking and Semen Quality: A New Meta-analysis Examining the Effect of the 2010 World Health Organization Laboratory Methods for the Examination of Human Semen. *European Urology*, 70(4), 635-645.
- Smith AMA, Ferris JA, Simpson JM, et al. (2010). Cannabis Use and Sexual Health. *The Journal of Sexual Medicine*, 7(2), 787-793.
- Sun AJ, Eisenberg ML. (2017). Association Between Marijuana Use and Sexual Frequency in the United States: A Population-Based Study. *The Journal of Sexual Medicine*, 14(11), 1342-1347.
- Wagner G, Fugl-Meyer K, Fugl-Meyer A. (2000). Impact of erectile dysfunction on quality of life: patient and partner perspectives. *International Journal of Impotence Research*, 12(S4), S144-S146.
- Warner EA. (1993). Cocaine Abuse. *Annals of Internal Medicine*, 119(3), 226.
- Weatherby NL, Shultz JM, Chitwood DD, et al. (1992). Crack Cocaine Use and Sexual Activity in Miami, Florida. *Journal of Psychoactive Drugs*, 24(4), 373-380.
- WHO. (1975). Education and Treatment in Human Sexuality?: The Training of Health Professionals, 1974. World Health Organization

technical report series?; no. 572. Geneva: World Health Organization. Available at: <https://apps.who.int/iris/handle/10665/38247>.

WHO. (2019). WHO global report on trends in prevalence of tobacco use 2000-2025, third edition. Available at: <https://escholarship.org/content/qt0z43b5dv/qt0z43b5dv.pdf>.

Wong DHW, Jenkins LC. (1974). An

experimental study of the mechanism of action of ketamine on the central nervous system. *Canadian Anaesthetists Society Journal*, 21(1), 57-67.

Zemishlany Z, Aizenberg D and Weizman A. (2001). Subjective effects of MDMA ('Ecstasy') on human sexual function. *European psychiatry?: the journal of the Association of European Psychiatrists*, 16(2), 127-30.